Eli Lilly Announces Positive Results for Orforglipron in Phase 3 ATTAIN-2 Trial 2025-09-02
On August 26, 2025, Eli Lilly and Company announced that their small molecule GLP-1 receptor agonist, Orforglipron, achieved positive results in the third phase 3 clinical trial, ATTAIN-2.
Read More